Exelixis reported $92.04M in Pre-Tax Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US USD -26415000 7.15M
Agios Pharmaceuticals AGIO:US USD -81747000 10.06M
AstraZeneca AZN:LN USD 3.09B 52M
Bluebird Bio BLUE:US USD -76513000 16.99M
Cytokinetics CYTK:US USD -142310000 122.49M
Eisai 4523:JP JPY -1588000000 11.31B
Esperion Therapeutics ESPR:US USD -55117000 11.21M
Exelixis EXEL:US USD 92.04M 3.53M
Genmab GEN:DC DKK 3.27B 783M
Immunogen IMGN:US USD -77755000 15.73M
Macrogenics MGNX:US USD -24813000 16.49M
Mirati Therapeutics MRTX:US USD -173307000 3.14M
Nektar Therapeutics NKTR:US USD -59204000 99.76M
Neurocrine Biosciences NBIX:US USD 97.9M 121.2M
Novartis NOVN:VX USD 4.06B 72M
Pfizer PFE:US USD 10.67B 3.11B
Takeda 4502:JP JPY 64.55B 90.92B
Ultragenyx Pharmaceutical RARE:US USD -238819000 80.96M
Xencor XNCR:US USD -31671000 2.3M
YTE INCY:US USD 178.22M 131.36M